EU Panel Backs Frontline Pembrolizumab Combo for Nonsquamous NSCLC

July 30, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, regardless of PD-L1 expression. The CHMP recommendation is based on the phase III KEYNOTE-189 trial, in which patients with … (leggi tutto)